Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology derived from an invention by clinicians from Stanford University. It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France. For more information, please visit:

Medical Devices

Anne Osdoit

Anne joined Sofinnova Partners in 2019 after having been Venture Partner for several years. She has been the CEO of SafeHeal (MD Start II’s first company) for 2 years, and is currently transitioning out of the company to focus on being the CEO of Ablacare (MD Start II’s third company). Upon closing of ...